⚖UPC-Intel
🇪🇺 UPC

UPC_CFI_2192/2026

Court
Brussels Local Division
Type of action
procedural
Patent
EP3689383
CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
Language
en
Claimant / applicant
  • TER MEER STEINMEISTER & PARTNER PATENTANWÄLTE MBB
  • TER MEER STEINMEISTER & PARTNER
  • JANSSEN BIOTECH, INC.
  • JANSSEN PHARMACEUTICALS INC.
  • JANSSEN-CILAG INTERNATIONAL NV
  • JANSSEN PHARMACEUTICA NV
  • JANSSEN-CILAG NV
  • JANSSEN BIOLOGICS B.V.
  • JANSSEN-CILAG A/S
  • JANSSEN-CILAG FARMACEUTICA LDA.
  • LEGEND BIOTECH CORPORATION
  • LEGEND BIOTECH USA INC.
  • LEGEND BIOTECH IRELAND LIMITED; AND
  • LEGEND BIOTECH BELGIUM BV
Defendant / respondent
  • INC. (2) JOHNSON & JOHNSON (3) JANSSEN BIOTECH
  • The Claimant’s Statement of Claim relating to claim construction
  • DEFENDANTS UPC_CFI_029/2026
  • INTERVENER UPC_CFI_029/2026
  • The Judge-Rapporteur set out a procedural agenda, giving the respondents the
  • Art. 10 and 45 UPCA lay down the general principle that the register is public and
  • In order to enable the Judge-Rapporteur to weigh up the interests set out in Art. 45 UPCA
  • CLAIMANT UPC_CFI_029/2026
  • The Defendants’ Counterclaims for revocation against EP 3 689 383 B1
  • All respondents requested the dismissal of the request in their respective comments.
  • The Request relates to UPC-actions UPC_CFI_29/2026
  • Essentially, the Respondents follow the same line of argument, which will be dealt with
  • The CoA has provided guidance on the application of Rule 262.1 RoP in the following
  • When considering the aforementioned interests, the CoA stated clearly that the public
  • After setting the legal background, the Applicant argues as follows:
  • 2SEVENTY BIO, INC.

Track this case

Get an email when a new order or decision is published in UPC_CFI_2192/2026.

Decisions and documents (1)

Weekly digest

A weekly email summarising new published decisions across European patent courts.